Today: 9 June 2026
CBA share price: Commonwealth Bank stock in focus before the RBA call and February earnings
18 January 2026
1 min read

CBA share price: Commonwealth Bank stock in focus before the RBA call and February earnings

Sydney, January 18, 2026, 17:07 AEDT — Market closed

  • Shares of Commonwealth Bank closed up Friday, capping a strong week for Australian financial stocks
  • Movements in fixed mortgage rates have intensified the market’s attention on where interest rates are headed
  • Investors are eyeing the RBA’s early-February move along with CBA’s half-year earnings due Feb. 11

Shares of Commonwealth Bank of Australia ended Friday’s session 0.52% higher at A$154.30, fluctuating between A$152.89 and A$155.29 during the day. The stock wrapped up the week with gains ahead of the weekend.

Banks lifted Australian shares to an 11-week peak in the last session, sending the S&P/ASX 200 up 0.48% to 8,903.9. IG market analyst Tony Sycamore noted that strength in U.S. banks was boosting local confidence, describing it as “a really solid week.” Seymour Telegraph

This matters because CBA dominates the market. When it moves, the index usually follows, and traders often track the rates narrative even without new company updates.

Mortgage pricing is shifting. This week, Commonwealth Bank hiked owner-occupier fixed home loan rates by as much as 0.7 percentage points, pushing its lowest two-year fixed rate to 5.79%. Macquarie Bank followed, increasing fixed rates by 0.25 percentage points, according to a report. “The fixed rate market continues to factor in the possibility of a higher cash rate,” said Canstar data insights director Sally Tindall. 9News

The Reserve Bank of Australia’s first policy meeting of the year is set for February 2–3. The cash-rate decision will be announced at 2:30pm AEDT on February 3, according to the ABC.

Bond yields have returned to focus. Australia’s 10-year government bond yield climbed to 4.71% on January 16, according to Trading Economics data — a shift that impacts banks by influencing funding costs and shaping investor views on future profits.

CBA’s calendar points to another key event. The bank will report half‑year results and declare its interim dividend on February 11. The ex‑dividend date is set for February 18, with the record date following on February 19, according to the company’s financial calendar.

Westpac, NAB, and ANZ move in lockstep with each other. Changes in mortgage rates, deposit battles, or shifts in bad-debt forecasts usually ripple through the group at once—though these trends often surface earliest at CBA.

Investors will zero in on net interest margin — the difference between what banks earn on loans and pay on deposits — along with loan growth and credit losses. These factors could complicate the straightforward “rates up is good” narrative.

The risk here: higher fixed rates might slow new lending more than they boost pricing. Plus, deposit competition could prove tougher than anticipated. If the RBA surprises with a hold or a softer stance, it could undercut the bank rally that pushed the sector into the weekend.

The next key dates are packed tightly: the RBA decision lands on February 3, followed by CBA’s half-year results and interim dividend announcement on February 11.

Stock Market Today

  • GSK to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline
    June 9, 2026, 9:41 AM EDT. GSK announced a $10.6 billion cash acquisition of U.S.-based Nuvalent, offering $124 per share, a 40% premium. The purchase aims to strengthen GSK's oncology portfolio ahead of patent expiries on key HIV treatments. Nuvalent awaits FDA decisions on two lung cancer drugs, zidesamtinib and neladalkib, with potential 2027 market entry. The deal also includes earlier-stage cancer treatments, including NVL-330. Nuvalent shares rose nearly 39% premarket, while GSK shares slipped 1.4%. GSK plans to finance the deal through debt and cash, expecting sales and profit boosts from 2027 and 2029, respectively, without impacting its credit rating. The acquisition intensifies GSK's lung cancer market presence, competing with firms like AstraZeneca, Roche, and Pfizer.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
MediaTek stock price: Taiwan chip designer closes higher as AI trade lifts sentiment — what to watch next
Previous Story

MediaTek stock price: Taiwan chip designer closes higher as AI trade lifts sentiment — what to watch next

Singapore Airlines stock price: Air India pact in focus after C6L closes at S$6.35
Next Story

Singapore Airlines stock price: Air India pact in focus after C6L closes at S$6.35

Go toTop